journal
MENU ▼
Read by QxMD icon Read
search

P & T: a Peer-reviewed Journal for Formulary Management

journal
https://www.readbyqxmd.com/read/30410286/research-briefs
#1
(no author information available yet)
No abstract text is available yet for this article.
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30410285/2018-european-association-for-the-study-of-diabetes
#2
Walter Alexander
We review sessions on the association of diuretic use and amputations, albiglutide and cardiovascular outcomes with diabetes and cardiovascular disease, how lorcaserin affects diabetes in overweight patients, how testosterone therapy improves diabetes in hypogonadal men, the pros and cons of gastric bypass surgery, how low-calorie sweeteners affect the gut microbiome, and more.
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30410284/angiotensin-ii-brings-more-questions-than-answers
#3
Nicholas Farina, Alexandra Bixby, Cesar Alaniz
The approval of synthetic human angiotensin II (Giapreza, LaJolla Pharmaceuticals) by the FDA in December 2017 provides clinicians with a new tool in the treatment of distributive shock. Angiotensin II (ATII) was approved based on the results of the ATHOS-3 trial. In this trial, patients who received angiotensin II were more likely to achieve a mean arterial pressure of 75 mmHg or an increase in mean arterial pressure of 10 mmHg above that seen in patients who received a placebo. However, the results of ATHOS-3 also highlighted important concerns about thrombotic and infectious complications associated with ATII...
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30410283/improving-medication-history-at-admission-utilizing-pharmacy-students-and-technicians-a-pharmacy-driven-improvement-initiative
#4
Katerina Petrov, Ranjani Varadarajan, Martha Healy, Elmira Darvish, Cathleen Cowden
Background: Because of the frequency of medication errors related to care transitions, patient-safety initiatives have recently focused on improving the patient medication list. Pharmacy student and technician participation in the medication-history process has been shown to improve the quality of medication histories. To improve patient care, a pharmacy-driven medication-history service utilizing a unique hybrid team of pharmacy students and technicians was launched at Inova Loudoun Hospital (ILH)...
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30410282/contemporary-prescription-patterns-of-adenosine-diphosphate-receptor-inhibitors-in-acute-coronary-syndrome
#5
Ellen B Yin, Huy Nguyen, Ishan Kamat, Maryam Bayat, Mahboob Alam
Purpose: To assess the contemporary use of adenosine diphosphate (ADP) receptor inhibitors in acute coronary syndrome at a large, quaternary academic medical center. Methods: A retrospective observational study was conducted using health records to compare patients who were treated with ticagrelor (Brilinta, AstraZeneca), prasugrel, or clopidogrel for a primary diagnosis of new-onset acute coronary syndrome between January 2014 and December 2014. Results: A total of 275 patients were identified...
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30410281/baxdela-tm-delafloxacin-a-novel-fluoroquinolone-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections
#6
Alexandra Adler, Saira Chaudhry, Tamara Goldberg
Baxdela (delafloxacin) for treatment of acute bacterial skin and skin structure infections.
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30410280/pharmaceutical-approval-update
#7
Michele B Kaufman
Arakoda (tafenoquine) for malaria; Annovera (segesterone acetate and ethinyl estradiol vaginal system) for contraception; and Oxervate (cenegermin-bkbj) for neurotrophic keratitis.
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30410279/drug-and-device-news
#8
(no author information available yet)
Approvals, new indications, regulatory activities, and more.
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30410278/federal-safe-harbor-for-value-based-contracts-being-considered-p-t-committees-can-receive-data-beyond-the-drug-label
#9
Stephen Barlas
P&T committees may soon have access to more than drug-label information as HHS considers implementing a safe harbor for value-based contracts between drug manufacturers and health insurers.
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30410277/selected-medication-safety-risks-that-can-easily-fall-off-the-radar-screen-part-3
#10
Matthew Grissinger
The final part of a 3-part series discusses medication safety risks related to labeling, patient education, and medication storage.
November 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271108/research-briefs
#11
(no author information available yet)
No abstract text is available yet for this article.
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271107/european-society-of-cardiology-congress-2018
#12
Walter Alexander
We review sessions on large-scale aspirin and anticoagulation trials, weight loss therapies, fish oil, gout, endocarditis, and cardiomyopathy, with important implications for health care providers.
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271106/emerging-therapies-for-patients-with-difficult-to-treat-migraine
#13
Troy Kish
The landscape of migraine therapy is set to change with the introduction of new classes of medications aimed at providing options for patients who have not responded to previous therapies. However, the pricing of the new agents will likely be a key determinant in the extent of their use in clinical practice.
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271105/enoxaparin-dosing-and-antixa-monitoring-in-specialty-populations-a-case-series-of-renal-impaired-extremes-of-body-weight-pregnant-and-pediatric-patients
#14
Tania Ahuja, Katie Mariam Mousavi, Liana Klejmont, Sonya Desai
The use of enoxaparin in specialty populations-including those with renal dysfunction, extremeness of body weight, pregnant patients, and pediatric patients-has not been studied in clinical trials. Monitoring anti-factor Xa activity (antiXa) as a surrogate to measure the activity of enoxaparin may be of interest. A case series of patients admitted to New York University Langone Health between December 2012 and July 2014 who received at least three consecutive doses of enoxaparin for the treatment of VTE and had a peak antiXa level drawn at steady state were evaluated...
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271104/views-conflict-on-trump-s-drug-pricing-blueprint-most-actions-face-political-legal-and-technical-roadblocks
#15
Stephen Barlas
President Donald Trump's wide-ranging Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs has implications for P&T committees, PBMs, drug manufacturers, insurers, and of course, patients. As with everything else involving health care, it's complicated.
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271103/naldemedine-symproic-for-the-treatment-of-opioid-induced-constipation
#16
Kenneth Hu, Mary Barna Bridgeman
Naldemedine (Symproic) for opioid-induced constipation.
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271102/pharmaceutical-approval-update
#17
Mary Choy
Ivosidenib (Tibsovo) for acute myeloid leukemia; elagolix (Orilissa) for endometriosis; and mogamulizumab-kpkc (Poteligeo) for mycosis fungoides or S├ęzary syndrome.
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271101/drug-and-device-news
#18
(no author information available yet)
Approvals, new indications, regulatory activities, and more.
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271100/fda-finalizes-drug-communication-guidance-p-t-committees-can-receive-data-beyond-the-drug-label
#19
Stephen Barlas
The FDA has made it easier for P&T committees to make formulary coverage decisions by expanding the health care economics information that drug manufacturers can provide to them.
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/30271099/selected-medication-safety-risks-that-can-easily-fall-off-the-radar-screen-part-2
#20
Matthew Grissinger
Part 2 of a 3-part series discusses medication safety risks related to labeling, patient education, and medication storage.
October 2018: P & T: a Peer-reviewed Journal for Formulary Management
journal
journal
30579
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"